InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF) latest research and development deal with ATERA SAS will support the advancement of its INM-750 targeting epidermolysis bullosa. The topical cannabinoid product assists in modulating keratin levels in people suffering with EB while simultaneously curing inflammation, wound healing, itching, pain and skin regeneration. Management intends to start Phase I clinical studies next year after closing additional pre-clinical work.
The highlights
ATERA specializes in the advancement, validation, commercialization and manufacturing of advanced tissue models as cost-effective, high-quality, reliable and more conscientious alternatives for animal trials. Under the deal, ATERA will advance 3D human skin models of Epidermolysis Bullosa to assess the efficiency of INM-750 and probe the beneficial effects of topically put INM-750 at ultra-structural molecular and cellular levels.
Dr. Sazzad Hossain, the CSO of InMed Pharmaceuticals, reported that INM-750 has shown significant prospect in pre-clinical models to resolve symptomatic improvement of Epidermolysis Bullosa including accelerated wound healing and a decline in pain, inflammation and itch. This project with ATERA is intended to assess the prospect that INM-750 holds to have an impact in ailment reversal, further supporting their current data showcasing up-regulation in certain keratins in the skin.
Read More